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 CURRENTOPINION Perioperative bleeding management in pediatric
patients
Susan M. Goobiea and Thorsten Haasb
Purpose of review
Managing the bleeding pediatric patient perioperatively can be extremely challenging. The primary goals
include avoiding hypotension, maintaining adequate tissue perfusion and oxygenation, and maintaining
hemostasis. Traditional bleeding management has consisted of transfusion of autologous blood products,
however, there is strong evidence that transfusion-related side-effects are associated with increased
morbidity and mortality in children. Especially concerning is the increased reported incidence of
noninfectious adverse events such as transfusion-related acute lung injury, transfusion-related circulatory
overload and transfusion-related immunomodulation. The current approach in perioperative bleeding
management of the pediatric patient should focus on the diagnosis and treatment of anemia and
coagulopathy with the transfusion of blood products only when clinically indicated and guided by goal-
directed strategies.
Recent findings
Current guidelines recommend that a comprehensive multimodal patient blood management strategy is
critical in optimizing patient care, avoiding unnecessary transfusion of blood and blood product and
limiting transfusion-related side-effects.
Summary
This article will highlight current guidelines in perioperative bleeding management for our most vulnerable
pediatric patients with emphasis on individualized targeted intervention using point-of-care testing and
specific coagulation products.
Keywords
blood conservation techniques, blood product transfusion, pediatric bleeding management,
thromboelastometry
INTRODUCTION
Major pediatric surgery and trauma may be associ-
ated with significant blood loss. Risk factors for
major bleeding can be divided into patient factors
(such as underlying inherited or acquired bleeding/
clotting disorders) and surgical/traumatic factors. As
much as 60–90% of infants and children under-
going liver transplant, cardiac or cranial surgery
receive blood products [1].
Massive hemorrhage is defined as blood
loss exceeding one circulating blood volume
within a 24-h period or blood loss of 50% of
circulating blood volume within a 3-h period or
transfusion rate equal to 10% of circulating blood
volume every 10min. A transfusion threshold of
40ml/kg of all blood products given in the first
24h was identified as putting critically injured
children at high risk for early and in-hospital
death [2].
BLEEDING AND BLOOD TRANSFUSION:
MORBIDITY AND MORTALITY
In pediatric major surgery, meticulous attention
must be given to maintaining normovolemia as
hypovolemia due to blood loss is the most common
identifiable cause of anesthesia-related cardiac
arrest, and is responsible for at least 12% of all
cardiac arrests in children [3]. Although traditional
bleeding management, consisting of transfusion of
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autologous blood products, offers a fairly acceptable
safety profile, there is strong evidence that trans-
fusion-related side-effects are associated with
increased morbidity and mortality in children
[4,5]. The rate of death corresponds to two per
100000 blood products transfused. The three main
causes of mortality are transfusion-related acute
lung injury, transfusion-related acute circulatory
overload and hemolytic transfusion reactions with
mortality rates as high as 15–30% [5]. Other risks
include transfusion-transmitted infection and trans-
fusion-related immunomodulation. Furthermore,
bleeding and resuscitation can be associated
with electrolyte abnormalities (such as hypocalce-
mia, hypomagnesemia, hypokalemia, hyperkalemia
and/or citrate toxicity) and a lethal triad of acidosis,
hypothermia and coagulopathy [6]. Massive blood
transfusion in pediatric trauma, surgery and critical
care has been identified as an independent predictor
of multiple organ failure, systemic inflammatory
response syndrome, increased infection and
increased mortality [7]. Massive pediatric transfu-
sion is independently associated with an increased
24-h mortality (odds ratio 2.50) and in-hospital
mortality (odds ratio 2.58) [2]. Early recognition,
appropriate and timely treatment of major blood
loss and its consequences are vital to reducing mor-
bidity and mortality.
PREVENTION OF PREOPERATIVE
BLEEDING: BLOOD CONSERVATION
TECHNIQUES
Judicious perioperative care should involve the use
of multimodal blood conservation techniques to
minimize bleeding and related complications of
allogeneic blood product transfusion. The World
Health Organization and the American Medical
Association recommend that the implementation
of comprehensive strategies for patient blood man-
agement be the focus in perioperative transfusion/
coagulation management to improve safety [8].
Indeed, patient blood management programs, as
recommended by organizations such as Society for
the Advancement of Blood Management and the
American Association of Blood Banks, have been
shown to reduce in-hospital blood product trans-
fusion, mortality and costs [9,10].
Preoperatively, diagnosis and treatment of ane-
mia by delaying elective surgery, iron supplement-
ation or administering recombinant human
erythropoietin has been described [11,12]. The
incidence of preoperative anemia in neonates is as
high as 37% in US hospitals and is an independent
risk factor for neonatal postoperative mortality,
increasing the incidence by at least two-fold [13
&
].
Preoperative autologous blood donation may be
offered in an older child, but problems with this
process include issues with incomplete donations,
wastage, clerical error, blood storage issues and ren-
dering the child anemic preoperatively.
Intraoperatively, there are a number of options
that should be used in combination [14]. Careful
fluid management to avoid hemodilution, optimiz-
ing tissue oxygenation and minimizing tissue
oxygen consumption are imperative. Employing a
restrictive transfusion practice (setting a transfusion
target of a hemoglobin 7g/dl instead of 9 g/dl) has
been shown to be safe in the pediatric ICU setting
and should be considered if the patient is hemody-
namically stable [15,16], although evidence is lack-
ing on the safest strategy for the neonatal
population [17]. Hypothermia, in combinationwith
acidosis, inevitably leads to an impaired coagulation
process and may, therefore, worsen bleeding. Thus,
forced-air warming should be rigorously performed
and temperature, as well as pH values, measured.
Surgical techniques can help control bleeding
and include pre-emptive tumor vessel or arterio-
venous malformation embolization, minimally
invasive surgery and using topical haemostatic
agents. Intraoperative blood/cell salvage is another
option that involves collecting autologous blood
from the surgical site to be processed and given back
to the patient during the surgery [18,19]. Contra-
indications include tumor surgery (potential dis-
semination of tumor cells) and the use of agents
that would result in red blood cell lysis (sterile water,
alcohol and hydrogen peroxide) and clotting agents
(surgical and gelfoam), contaminants (urine, bone
and infection) and irrigating solutions.
Postoperatively, the avoidance of hemodilution,
careful hemodynamic control, minimizing blood
draws and other causes of iatrogenic blood loss,
utilizing restrictive transfusion guidelines and blood
product transfusion protocols should be considered.
Table 1 details these pediatric patient blood
management strategies.
KEY POINTS
 A comprehensive multimodal patient blood
management strategy is critical in optimizing pediatric
patient care.
 Transfusion of allogeneic blood products should be
performed only when clinically indicated and guided
by goal-directed strategies.
 The use of ROTEM or thrombelastography has been
demonstrated to be extremely useful in detecting
coagulopathies and guiding bleeding management.
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DIAGNOSIS OF PERIOPERATIVE
BLEEDING: VISCOELASTIC TESTING VS.
STANDARD LABORATORY WORK-UP
The cause of haemostatic changes during pediatric
major surgery and trauma is multifactorial and may
be related to dilutional coagulopathy, hyperfibrinol-
ysis, surgical complexity with increased blood loss
and the consecutive loss of coagulation factors [20].
Fibrinogen is the first coagulation factor that
achieves a critical low value during massive blood
loss, whereas all other factors seem to be less affected
by blood loss and hemodilution [21]. In addition,
tissue injury can produce tissue activators (tissue
plasminogen activator, urokinase and kallikrein)
and activate plasmin from plasminogen, which
can cause a shift from physiological fibrinolysis to
hyperfibrinolysis. This hyperfibrinolysis decreases
clot stability and increases bleeding tendency,
by increasing consumption of fibrinogen and coagu-
lation factors. Plasmin induces many other
responses that contribute to coagulopathy and
bleeding, including activation of thrombin gener-
ation, cleavage of fibrinogen to fibrin and cleavage
of receptors on platelets [22]. This in turn starts a
vicious cycle of coagulopathy and inflammation in
the bleeding child.
Thus, the presence of this multifactorial cause
necessitates the use of a fast and reliable test to
diagnose the cause and treat the bleeding properly.
The most recently published guidelines recommend
performance of standard plasmatic coagulation test-
ing [23
&
], however, there is actually no sound evi-
dence from well-designed studies to confirm the
usefulness of those test results for the diagnosis of
coagulopathy or to guide haemostatic therapy. The
unacceptable time delay seems to be the one reason
why bleeding management may be performed
empirically without a clear, targeted therapeutic
focus. Notably, viscoelastic point-of-care such as
thromboelastometry (ROTEM) or thrombelastogra-
phy has been shown to be effective in guiding
perioperative bleeding management [23
&
,24–33].
Such tests have been shown to be effective at reduc-
ing the transfusion of any allogeneic blood products
and they also offer a substantial cost saving [34,35
&
].
However, the insensitivity to the effect of antipla-
telet drugs and to the inhibition of nonthrombin-
activated platelet pathways is the main limitation of
viscoelastic tests and should be acknowledged.
Table 1. Pediatric patient blood management strategies
Preoperative Intraoperative Postoperative
Schedule optimal timing for procedure Maximize tissue oxygen delivery Optimize ventilation, cardiac output and tissue
oxygenation
Avoid unnecessary laboratory work-up Minimize tissue oxygen consumption Optimize fluid management; avoid
hemodilution
Clear structured bleeding anamnesis Careful blood pressure management Education of medical professional in PBM goals
Early diagnosis and treatment of
anemia
Optimize fluid management; avoid
hemodilution
Tolerate anemia if possible
Stimulate erythropoiesis Keep normothermia, avoid acidosis Treat anemia with iron therapy
Education of medical professionals in
PBM goals
Clear algorithm for bleeding
management
Stimulate erythropoiesis
Implementation of PBM program Optimize surgical technique and
consider blood-sparing alternatives
Limit iatrogenic blood loss
Usage of topical hemostatic agents Reduce amount and volume of laboratory blood
draws
Antifibrinolytics Clear algorithm for blood product transfusion
POC assessment of hemostasis Avoid treatment of impaired standard
laboratory tests without clinical relevance
Usage of cell salvage Treat coagulopathy with vitamin K if indicated
Usage of purified coagulation factors
whenever possible and when available
Tolerate coagulopathy if possible
Restrictive transfusion practice Consider antifibrinolytic treatment
Transfusion of appropriate type and
volume blood products when
necessary; avoid unnecessary and
overtransfusion
PBM, patient blood management; POC, point-of-care.
Pediatric anesthesia
354 www.co-anesthesiology.com Volume 29  Number 3  June 2016
 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
Future decision-makers should consider the use
of such point-of-care testing as a mandatory com-
ponent of the routine work-up of hemostatic man-
agement during major pediatric surgery.
MANAGEMENT OF THE BLEEDING CHILD
Fluid management: crystalloids and colloids
The goal of intraoperative fluidmanagement should
be to maintain normovolemia while avoiding
hypervolemia to minimize swelling, edema and
hemodilution.
Ringers Lactate (273 mOsm) and Plasmalyte
(294 mOsm) are preferred as they are associated
with less severe acidosis than isotonic saline [36].
It seems prudent to replace blood loss initially by
administration of crystalloids or colloids in a 2 : 1
ratio of estimated blood loss. However, if losses are
rapid and at least 20% of estimated blood volume in
an infant below 10kg, administering colloids in a
1 : 1 ratio may be required to maintain hemody-
namic stability. In a recent meta-analysis, it was
concluded that colloids and crystalloids can be sim-
ilarly used for fluid resuscitation [37].
Low cardiac output states and hypotension
should be avoided as this leads to decreased tissue
oxygen delivery and should be rapidly treated and
temporized by instituting vasopressors along with
aggressive fluid and blood product resuscitation as
clinically indicated [38].
Transfusion of blood and platelets
Universal transfusion guidelines recommend
against a single transfusion trigger [23
&
,38], how-
ever, maintenance of a hemoglobin level at 8 g/dl is
an accepted standard during massive intraoperative
blood loss [4], while in stable critically ill children, a
threshold of 7 g/dl might be sufficient [39]. This
corresponds to hematocrits between 21 and 25%
and should provide an impetus for blood transfu-
sion taking into consideration clinical status of the
child and the potential for ongoing blood loss. As a
rule of thumb, the required transfusion volume of
packed red blood cells in children can be calculated
as follows: body weight (kg)  desired increment in
hemoglobin (g/dl)  5 [40]. Overtransfusion should
be avoided.
Expert consensus recommends that a minimal
platelet count of 50000 cells/ml should be main-
tained for patients with ongoing bleeding
[23
&
,38,41]. Platelet count can be expected to rise
by approximately 50000–100000 cells/ml after
transfusion of 5–10ml/kg of an apheresis platelet
concentrate. The transfusion of platelet concentrate
carries the highest risk of side-effects of all allogeneic
blood products (bacterial contamination of platelet
components is the second most common cause of
transfusion-related deaths in the USA) and therefore
should be performed cautiously [42].
Rapid transfusion of blood has been associated
with fatal hyperkalemia [43]. The ‘Wake Up Safe’
initiative from Society of Pediatric Anesthesia
recommends that RBC should be ‘fresh’, that is less
than 1-week old or washed if the patient is below
1-year old or weights less than 10kg to avoid hyper-
kalemia [44].
Transfusion of fresh frozen plasma,
cryoprecipitate or fibrinogen concentrate
Current clinical guidelines suggest replacing coagu-
lation factor deficiency with fresh frozen plasma
(FFP) at a dose of 10–15ml/kg when there is an
ongoing clinical bleeding and the prothrombin
time, partial thromboplastin time and International
Normalized Ratio are 1.5 times normal. Notably,
evidence-based data supporting this approach are
lacking [45
&
]. However, there appears to be an over-
use of plasma for indications that have never proven
to be beneficial [46,47]. Accumulating data suggest
that acquired fibrinogen deficiency seems to be
the leading determinant in the development of
perioperative dilutional coagulopathy [20,21,38].
Current guidelines support the substitution of fibri-
nogen if below 150–200mg/dl or maximum clot
firmness in the ROTEM FIBTEM assay is less than
8mm [38,48]. Treatment of acquired fibrinogen
deficiency consists traditionally of transfusion of
FFP or cryoprecipitate, or administration of purified
fibrinogen concentrate. Although frequently used,
the recommended dosages for FFP [49] may not be
adequate to achieve a clinically meaningful
improvement in fibrinogen deficiency and therefore
cryoprecipitate of fibrinogen substitute is preferred
[50]. Cryoprecipitate contains higher concen-
trations of fibrinogen as compared with FFP, but
was withdrawn from European countries because of
risk of immunologic reactions and potential trans-
mission of infectious agents [51]. Alternatively,
intraoperative substitution with fibrinogen concen-
trate can be safely and effectively used to treat
fibrinogen deficiency [21,35
&
,52–54].
Transfusion of specific coagulation factors
Prothrombin complex concentrate (PCC) can help
correct dilutional coagulopathy by increasing
thrombin generation [55–57], however, data about
the effectiveness or optimal dosing of PCC for
pediatric perioperative bleeding are scarce [58].
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Acquired factor XIII deficiency appears preva-
lent even in major pediatric surgery, but no sound
data exist on pediatric FXIII supplementation
[25,35
&
].
Recombinant factor VIIa (rFVIIa) has been
described as useful for controlling severe bleeding
in cardiac [59–61] and neurosurgical procedures in
children [62–64], although a prospective, random-
ized trial in pediatric cardiac surgery failed to prove a
significant difference in blood loss following admin-
istration of rFVIIa compared to placebo [65]. Thus,
there are insufficient data to make any evidence-
based recommendations concerning the efficacy of
rFVIIa as prophylactic, routine or rescue therapy in
pediatric perioperative bleeding management [66].
Massive transfusion protocol
The goal of a massive transfusion protocol (MTP) is
to avoid coagulopathy as a consequence of platelet
and clotting factor depletion secondary to trans-
fusion restricted to packed red blood cells. For the
treatment of massive hemorrhage in adult trauma
patients, early and aggressive transfusion of FFP in a
1 : 1 ratio with packed red blood cells may improve
survival [67–69]. Such MTPs, using fixed ratios of
blood products (RBC:FFP:Platelets in a ratio of
1 : 1:1), may improve outcome in coagulopathic
military and civilian adult trauma patients, but
there is a paucity of data on the efficacy of MTP
for pediatric trauma patients, whose mechanism of
injury may differ from those in adults. Also, it is
unclear how this strategy pertains to managing
massive blood loss in the pediatric surgical patient.
Even if MTPs are feasible to perform in
pediatrics, they are associated with increased blood
product transfusion with no increased survival in
children. The value of aggressive blood product
transfusion using MTPs for the pediatric patient
with massive hemorrhage requires further prospec-
tive validation [70–73].
ANTIFIBRINOLYTICS
There is strong evidence that the implementation of
a patient blood management strategy involving
intraoperative prophylactic administration of anti-
fibrinolytics is efficacious (with a good safety pro-
file) at decreasing bleeding in trauma, cardiac,
craniofacial and scoliosis surgery [22,74–78]. Tra-
nexamic acid (TXA) is the most common antifibri-
nolytic used worldwide as epsilon aminocaproic
acid (EACA) is not available in many countries (such
as Canada, New Zealand and most of Europe). Cra-
niosynostosis patients who were not treated with
TXAhad an increased odds ratio of 2.6 for all adverse
postoperative events not only related to decreased
blood loss [79]. Similarly, EACA decreases blood loss
and transfusion in observational and retrospective
analysis [80,81]. There are a wide variety of dosage
schemes for TXA and EACA reported in mostly
single center trials, however, to maximize efficacy
and minimize side-effects, guidelines should be
based on pharmacokinetic data [82]. On the basis
of pharmacokinetic data and modeling, a TXA load-
ing dose of 10mg/kg over 15min followed by a
5mg/kg/h maintenance infusion may be sufficient
to maintain adequate TXA plasma concentrations
during craniosynostosis surgery; based on a pre-
sumed minimal TXA plasma concentration of
20mg/ml. For EACA, a loading dose of 100mg/kg
followed by an infusion of 40mg/kg/h has been
shown to maintain therapeutic plasma concen-
trations [22,83–85]. A recently completed pharma-
cokinetic/pharmocodynamic trial in scoliosis
surgery will provide better guidelines of the efficacy
and safety profile of TXA as well as the optimum
therapeutic plasma concentration and the most
effective dosage scheme [86].
There may also be a role of TXA in treating
subarachnoid hemorrhage in the prevention
of rebleeding and improvement in neurological
outcome [87,88] and an ongoing trial may answer
this question [89]. To date, there is an ongoing
Clinical Randomization of an Antifibrinolytic in
Significant Head Injury trial investigating the
efficacy and safety of TXA in traumatic pediatric
brain injury [90].
CONCLUSION
A comprehensive understanding of pathophysiol-
ogy of hematologic derangements and amultimodal
patient blood management strategy is crucial in
quickly and safely managing anemia and coagulop-
athy associated with massive intraoperative blood
loss during pediatric major surgery. The goals
should be to maintain hemodynamic stability, oxy-
gen carrying capacity and perfusion to vital organs.
Overtransfusion and transfusion-related side-effects
should be minimized. Future efforts should focus
on furthering the education of pediatric anesthesi-
ologists, surgeonsand intensivists regardingpediatric
patient blood management techniques with particu-
lar focus on goal-directed targeted diagnosis using
point-of-care testing and targeted therapy utilizing
currently unlicensed drugs (such as fibrinogen
and PCCs).
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